John E. Niederhuber, M.D.
Dr. Niederhuber is the Chairman of Aptevo Therapeutics’ Board of Directors. Dr. Niederhuber is currently Adjunct Professor of Surgery and Oncology the Johns Hopkins University School of Medicine and Deputy Director of the Johns Hopkins Clinical Research Network. He retired in April 2019 from his position as Executive Vice President Inova Health System, Fairfax, Virginia where he served (2010-2019) as the Chief Executive Officer and founder of the Inova Translational Medicine Institute, a not-for-profit genomics research institute. Dr. Niederhuber served as a director of Emergent from August 2010, until his resignation from the Emergent Board of Directors in May 2016. Dr. Niederhuber is the former Director of the National Cancer Institute (NCI), of the National Institutes of Health having been appointed to that position in 2006 by President Bush. Before assuming the NCI directorship, he chaired the National Cancer Advisory Board. Dr. Niederhuber has held a number of academic leadership positions including as Director of the University of Wisconsin Comprehensive Cancer Center and professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University School of Medicine from 1991 to 1997 and held professorships at the Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987 where he also served as Associate Dean for Research and Associate Dean Clinical Affairs. Dr. Niederhuber is a member of the National Academy of Medicine.
Mr. White has served as President and Chief Executive Officer, and as a Director of the Board of Aptevo Therapeutics since August 2016. Previously, Mr. White served as Chief Financial Officer of St. Vincent Health, and was responsible for finance, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to St. Vincent Health, Mr. White served as Chief Financial Officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking. Prior to his career in healthcare, Mr. White held leadership positions at General Motors, Hewlett-Packard, and Motorola, including financial roles within its Japan, South Asia and Latin America Cellular Group. He is currently a Director of the Board at OneAmerica Financial Partners and Emergent Biosolutions. Mr. White earned his B.S. in Accounting from Wilberforce University, an HBCU, and received an M.B.A. in Finance from Indiana University where he was awarded the Consortium Fellowship.
Daniel J. Abdun-Nabi
Mr. Abdun-Nabi served as the President and Chief Executive Officer of Emergent BioSolutions from April 2010 until his retirement from Emergent in April 2019. From May 2007 to March 2012, Mr. Abdun-Nabi served as Emergent’s President and Chief Operating Officer. Mr. Abdun-Nabi previously served as Emergent’s Corporate Secretary from December 2004 to January 2008, Emergent’s Senior Vice President, Corporate Affairs and General Counsel from December 2004 to April 2007 and Emergent’s Vice President and General Counsel from May 2004 to December 2004. Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a publicly traded company focused on the development and commercialization of vaccines, which was acquired by Baxter International Inc. in 2000. Mr. Abdun-Nabi is currently a member of the board of RegenxBio, a publicly traded clinical stage biotechnology company focused on the development of gene therapy product candidates for the treatment of various diseases.
Grady Grant, III
Mr. Grant has over 35 years of experience in pharmaceutical sales and marketing. He is currently serving as consultant Chief Commercial officer for Unpharma LLC, a commercial manufacturing organization specializing in Blo-Fill seal technology utilized in pharmaceutical as well as OTC formulations. Prior to this role, he served as Vice President of Sales for Tissue Tech Limited, an organization who pioneered the innovative application of human placental tissue in wound healing. From December 2011 to August 2018, he worked as Vice President of Medical Sales for Mead Johnson Nutrition, a public company focused on pediatric nutrition in the retail and medical setting. His tenure at Mead Johnson was preceded by 30 years of service at Eli Lilly and Company where he held various leadership positions in sales and marketing concluding his career as Vice President of Sales Neuroscience which he held from January 2006 to December 2011.
Zsolt Harsanyi, Ph.D.
Dr. Harsanyi serves on the Board of Directors of Emergent BioSolutions. Dr. Harsanyi has served as Chairman of the Board of N-Gene Research Laboratories, Inc., a privately-held biotechnology company, since March 2011. Prior to that, Dr. Harsanyi served as Chief Executive Officer and Chairman of the Board of Directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to February 2011. Dr. Harsanyi served as President of Porton International plc, or Porton International, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was Vice President of Corporate Finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress’ Office of Technology Assessment, served as a consultant to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell University Medical College.
Barbara Lopez Kunz
Ms. Kunz currently serves as President & CEO of the Drug Information Association, a health and life sciences think tank focused on advancing the science and policy underpinning healthcare globally. From 2007 to 2013, she served as President at Battelle, leading a $300M worldwide health and life sciences contract research business. From 2003 to 2007, she worked as Senior VP/GM for Thermo Fisher Scientific’s $1.2B Biosciences division, growing the portfolio through M&A. Prior roles include global business leadership roles at Croda International, DuPont, and senior R&D leadership roles at ICI, now Astra Zeneca.